[go: up one dir, main page]

MX2015016332A - Inhibidores de alk biciclicos fusionados. - Google Patents

Inhibidores de alk biciclicos fusionados.

Info

Publication number
MX2015016332A
MX2015016332A MX2015016332A MX2015016332A MX2015016332A MX 2015016332 A MX2015016332 A MX 2015016332A MX 2015016332 A MX2015016332 A MX 2015016332A MX 2015016332 A MX2015016332 A MX 2015016332A MX 2015016332 A MX2015016332 A MX 2015016332A
Authority
MX
Mexico
Prior art keywords
pyrrolotriazines
alk inhibitors
alk
inhibitors
compositions
Prior art date
Application number
MX2015016332A
Other languages
English (en)
Inventor
Gregory R Ott
Eugen F Mesaros
Ralph C Haltiwanger
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2015016332A publication Critical patent/MX2015016332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta solicitud proporciona compuestos de la fórmula general (I) (ver Fórmula) y/o una sal del mismo, en donde X, R1 y R2 son como se define en el presente documento. También se describen composiciones y usos terapéuticos.
MX2015016332A 2013-05-29 2014-05-28 Inhibidores de alk biciclicos fusionados. MX2015016332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361828451P 2013-05-29 2013-05-29
PCT/US2014/039755 WO2014193932A1 (en) 2013-05-29 2014-05-28 Pyrrolotriazines as alk inhibitors

Publications (1)

Publication Number Publication Date
MX2015016332A true MX2015016332A (es) 2016-07-20

Family

ID=50983214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016332A MX2015016332A (es) 2013-05-29 2014-05-28 Inhibidores de alk biciclicos fusionados.

Country Status (8)

Country Link
US (2) US9440984B2 (es)
EP (1) EP3004111A1 (es)
JP (1) JP2016520129A (es)
CA (1) CA2912806A1 (es)
HK (1) HK1222848A1 (es)
IL (1) IL242623A0 (es)
MX (1) MX2015016332A (es)
WO (1) WO2014193932A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN112094272A (zh) * 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115466264B (zh) * 2021-06-11 2024-12-10 腾讯科技（深圳）有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
WO2023101387A1 (ko) * 2021-11-30 2023-06-08 연세대학교 산학협력단 단백질 키나아제 저해활성을 가지는 2, 7-치환된 피롤로[2,1-f][1,2,4]트라아진 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
SG145749A1 (en) 2003-08-15 2008-09-29 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005080393A1 (en) 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2005230847B2 (en) 2004-03-31 2012-11-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors

Also Published As

Publication number Publication date
CA2912806A1 (en) 2014-12-04
WO2014193932A1 (en) 2014-12-04
JP2016520129A (ja) 2016-07-11
EP3004111A1 (en) 2016-04-13
HK1222848A1 (zh) 2017-07-14
IL242623A0 (en) 2016-02-01
US20160068535A1 (en) 2016-03-10
US9440984B2 (en) 2016-09-13
US20160347756A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
IN2014DN09346A (es)
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
IN2015DN00960A (es)
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
TW201613911A (en) Heterocyclic compounds and uses thereof
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
PH12016500676B1 (en) Pyrimidine fgfr4 inhibitors
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
IN2015DN00598A (es)
MX2016002794A (es) Compuestos antiproliferativos.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2015017156A (es) Inhibidores de bace.
MX2015008829A (es) Momelotinib deuterado.
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
EA201590729A1 (ru) Производные 3,4-дизамещенного оксазолидинона и их применение в качестве ингибиторов кальцийактивируемых калиевых каналов